Differences in patterns of care and outcomes between grade II and grade III molecularly defined 1p19q co-deleted gliomas

Weller, 2015, Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups, Acta Neuropathol, 129, 679, 10.1007/s00401-015-1409-0 Cancer Genome Atlas Research N, 2015, Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas, N Engl J Med, 372, 2481, 10.1056/NEJMoa1402121 Eckel-Passow, 2015, Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors, N Engl J Med, 372, 2499, 10.1056/NEJMoa1407279 Suzuki, 2015, Mutational landscape and clonal architecture in grade II and III gliomas, Nat Genet, 47, 458, 10.1038/ng.3273 Louis, 2016, The 2016 World Health Organization classification of tumors of the central nervous system: a summary, Acta Neuropathol, 131, 803, 10.1007/s00401-016-1545-1 (NCDB) NCDB. NCDB Overview. American College of Surgeons; 2015. Klabunde, 2002, Assessing comorbidity using claims data: an overview, Med Care, 40, 10.1097/00005650-200208001-00004 Deyo, 1992, Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases, J Clin Epidemiol, 45, 613, 10.1016/0895-4356(92)90133-8 Olar, 2015, IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas, Acta Neuropathol, 129, 585, 10.1007/s00401-015-1398-z Gorovets, 2012, IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma, Clin Cancer Res, 18, 2490, 10.1158/1078-0432.CCR-11-2977 NCCN. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Version 2.2016 ed2006. van den Bent, 2005, Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial, Lancet, 366, 985, 10.1016/S0140-6736(05)67070-5 Cairncross, 2013, Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402, J Clin Oncol, 31, 337, 10.1200/JCO.2012.43.2674 van den Bent, 2013, Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951, J Clin Oncol, 31, 344, 10.1200/JCO.2012.43.2229 Wick, 2009, NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide, J Clin Oncol, 27, 5874, 10.1200/JCO.2009.23.6497 Lassman, 2011, International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors, Neuro-oncology, 13, 649, 10.1093/neuonc/nor040 ClinicalTrials.gov. Phase III intergroup study of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy with adjuvant PCV chemotherapy in patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma (CODEL) NCT00887146. ClinicalTrials.gov: ClinicalTrials.gov; 2015. ClinicalTrials.gov. NRG BN005 A phase II randomized trial of proton vs. photon therapy (IMRT) for cognitive preservation in patients with IDH mutant, low to intermediate grade gliomas; 2018. Jaeckle, 2016, Neurology, 86 Buckner, 2016, Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma, N Engl J Med, 374, 1344, 10.1056/NEJMoa1500925 Pignatti, 2002, Prognostic factors for survival in adult patients with cerebral low-grade glioma, J Clin Oncol, 20, 2076, 10.1200/JCO.2002.08.121 Shirai, 2010, Influence of histological subtype on survival after combined therapy of surgery and radiation in WHO grade 3 glioma, J Radiat Res, 51, 589, 10.1269/jrr.10055 Mizoguchi, 2012, Molecular characteristics of glioblastoma with 1p/19q co-deletion, Brain Tumor Pathol, 29, 148, 10.1007/s10014-012-0107-z Labussiere, 2010, All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2, Neurology, 74, 1886, 10.1212/WNL.0b013e3181e1cf3a Wick, 2016, Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide, Neuro-oncology, 18, 1529